线粒体靶向缓释微球PLGA-(TEMPO+TPP-Ceria)对视网膜缺血再灌注损伤的作用及机制研究

视网膜缺血再灌注（RIR）损伤可以导致视神经节细胞（RGCs）的死亡，视网膜形态退化，最终导致视力丧失，目前尚无有效的治疗方法。线粒体靶向的联合用药在RIR损伤中的研究严重缺乏。我们的前期研究表明：2,2,6,6-四甲基哌啶-1-氧基（TEMPO）和氧化铈（Ceria）纳米颗粒对大鼠RGCs有抗氧化作用；TEMPO可促进视网膜前体细胞R28中Nrf2核转运。本项目我们将探讨以下内容：（1）体外PLGA-(TEMPO+TPP-Ceria)对RGCs和R28细胞的保护作用;（2）体内PLGA-(TEMPO+TPP-Ceria)对RIR损伤的延缓和逆转作用;（3）PLGA-(TEMPO+TPP-Ceria)对RIR损伤作用的分子机制。通过本项研究，我们将明确PLGA-(TEMPO+TPP-Ceria)在RIR损伤中的作用及分子机制，将为RIR损伤的临床治疗提供有力的理论基础。

Retinal ischemia-reperfusion (RIR) injury will cause the death of retinal ganglion cells (RGCs), degeneration of the retina, and loss of vision. However, there are no effective treatments currently. The combined treatments of mitochondria-targeted drugs are seriously lacking in the study of RIR injury. Our previous studies have shown that 2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPO) and cerium oxide (Ceria) nanoparticles have antioxidant effects on rat RGCs, and TEMPO can promote Nrf2 nuclear transport in retinal precursor cells R28. In this project, we will study the following contents: (1) the protective effect of PLGA-(TEMPO+TPP-Ceria) on RGCs in vitro, (2) the treatment effects of PLGA-(TEMPO+TPP-Ceria) on RIR injury in vivo, (3) molecular mechanisms of PLGA-(TEMPO+TPP-Ceria) on the treatment of RIR injury. Through this study, we will clarify the roles and molecular mechanisms of PLGA-(TEMPO+TPP-Ceria) in RIR injury, and will provide a strong theoretical basis for the clinical treatment of RIR injury.